Bleeding Events

Adjusted HR (95% CI) rivaroxaban vs Pradaxa®

No significant difference in the risk of thromboembolic stroke, mortality or acute myocardial infarction with rivaroxaban vs Pradaxa®

Retrospective cohort study of 118,891 US Medicare patients with NVAF who were 65 years or older and initiated treatment with standard doses of Pradaxa® (150mg b.d.) or rivaroxaban (20mg o.d.). Primary outcomes were: thromboembolic stroke, intracranial haemorrhage, major extracranial bleeding events, including major gastrointestinal bleeding, and mortality. Secondary outcomes were: all hospitalised extracranial bleeding events and acute myocardial infarction. Differences in baseline characteristics were adjusted using propensity scores. Mean duration of follow-up: 108 days (Pradaxa®) and 111 days (rivaroxaban).1

Bleeding Events

Adjusted HR (95% CI) rivaroxaban vs Pradaxa®

No significant difference in the risk of thromboembolic stroke, mortality or acute myocardial infarction with rivaroxaban vs Pradaxa®

Retrospective cohort study of 118,891 US Medicare patients with NVAF who were 65 years or older and initiated treatment with standard doses of Pradaxa® (150mg b.d.) or rivaroxaban (20mg o.d.). Primary outcomes were: thromboembolic stroke, intracranial haemorrhage, major extracranial bleeding events, including major gastrointestinal bleeding, and mortality. Secondary outcomes were: all hospitalised extracranial bleeding events and acute myocardial infarction. Differences in baseline characteristics were adjusted using propensity scores. Mean duration of follow-up: 108 days (Pradaxa®) and 111 days (rivaroxaban).1